HB 2008

Abstract

Health insurance; authorization of drug prescribed for the treatment of a mental disorder. Requires that any provider contract between a carrier and a participating health care provider with prescriptive authority, or its contracting agent, contain provisions that require, when a carrier has previously approved prior authorization for any drug prescribed for the treatment of a mental disorder listed in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association, no additional prior authorization can be required if (i) the drug is a covered benefit, (ii) the prescription does not exceed the U.S. Food and Drug Administration-labeled dosages, (iii) the prescription has been continuously issued for no fewer than three months, and (iv) the prescriber performs an annual review of the patient to evaluate the drug's continued efficacy, changes in the patient's health status, and potential contraindications. The bill provides that this requirement does not prohibit a carrier from requiring prior authorization for any drug that is not listed on its prescription drug formulary at the time the initial prescription is issued. The bill also provides that such provider contracts contain provisions requiring a carrier to honor a prior authorization issued by the carrier for a drug regardless if the drug is removed from the carrier's prescription drug formulary after the initial prescription for that drug is issued.

Health insurance; authorization of drug prescribedfor the treatment of a mental disorder. Requires that any providercontract between a carrier and a participating health care providerwith prescriptive authority, or its contracting agent, provide thatno prior authorization is required for any drug prescribed for thetreatment of a mental disorder listed in the most recent editionof the Diagnostic and Statistical Manual of Mental Disorders publishedby the American Psychiatric Association if the prescription (i) isa covered benefit, (ii) does not exceed the U.S. Food and Drug Administration-labeleddosages, and (iii) has been continuously issued for no fewer thanthree months. The bill provides that this requirement does not prohibita carrier from requiring step therapy for any drug that is not listedon its prescription drug formulary.